CA-BOEHRINGER-INGELHEIM
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
Press Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sit udbud inden for digital transformation med Silver Creek23.1.2026 14:25:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med Silver Creek, en førende virksomhed inden for datastrategi, analyse, applikationsudvikling og ai-drevne automatiseringstjenester. Silver Creek Software er en førende teknologivirksomhed, der er baseret i Alberta, Canada, med ekspertise i at transformere organisationer gennem data- og forretningsløsninger. Firmaet blev etableret i 1998 og tilbyder komplette konsulentydelser med speciale i data og analyse, applikationsudvikling, maskinlæring og ai. Med et team af erfarne og certificerede fagfolk leverer virksomheden skræddersyede løsninger på tværs af flere brancher, herunder den offentlige sektor, finansielle tjenester, naturressourcer og transport. Kernen i Silver Creeks arbejde er at skabe værdi ud fra kundens data gennem digitalisering, integration og automatisering. "Vi har opbygget vores omdømme på at hjælpe organisationer med at omdanne komplekse dataøkosystemer til strategiske aktiver," udtaler Ben Steem, administrerende dire
DCX Liquid Cooling Systems Announces New 8MW Coolant Distribution Unit, Optimized for 45°C Warm-Water Cooling in Next-Gen NVIDIA Vera Rubin AI Deployments23.1.2026 14:18:00 CET | Press release
DCX beats its own record of the most powerful CDU system ever made. Liquid cooling Manufacturer leads category of hyperscale CDUs, launching today a new CDU system with a stunning 8MW capacity, designed specifically for NVIDIA Vera Rubin 45°C warm water cooling DCX Liquid Cooling Systems is proud to announce the second generation Facility Distribution Unit (FDU V2AT2). Designed to support the infrastructure shift driven by AI deployments at scale, new CDU supports 45°C warm-water cooling for NVIDIA’s NVL72 GB200 / GB300 Blackwell and Vera Rubin architectures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123068139/en/ The Facility Coolant Distribution Unit—the new generation of liquid cooling for hyperscale data centers. FDU V2AT2 delivers up to 8.15MW of heat transfer capacity while providing record breaking flowrate, enabling 45°C warm-water operation—temperature level that can eliminate the need for chillers on the he
HUMAIN and Infra Announce AI and Digital Financing Framework Agreement23.1.2026 14:01:00 CET | Press release
HUMAIN and the National Infrastructure Fund (“Infra”) announced on the sidelines of the World Economic Forum (WEF) Annual Meeting 2026 in Davos, Switzerland, a Strategic Financing Framework Agreement of up to $1.2 billion to support the expansion of AI and digital infrastructure projects in the Kingdom of Saudi Arabia. The Framework Agreement outlines non-binding financing terms for HUMAIN’s development of up to 250 MW of hyperscale AI data center capacity. These data centers will deploy leading edge GPUs for AI training and inference and support HUMAIN’s local, regional and global customers. In addition, Infra and HUMAIN have agreed to explore the establishment of an AI data center investment platform. This would be anchored by the two organizations and structured to facilitate participation by global and local institutional investors to support further scaling of HUMAIN’s AI strategy. Today’s Framework Agreement underscores Infra’s key role in partnering with its counterparts to acce
Cyclic Materials Secures USD $75M Series C Funding to Fast-Track Local and Resilient Rare Earths Supply at Global Scale23.1.2026 13:00:00 CET | Press release
New equity investment will accelerate deployment of resilient, locally anchored rare earths recycling infrastructure enabling new streams of heavy rare earths supply for AI, robotics, defense and advanced manufacturing critical to the future of Western industry Cyclic Materials today announced it has closed an over-subscribed USD $75 million Series C equity round, its largest to date, scaling up operations across the US and Europe and accelerating Canada-based research and development footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123519008/en/ Cyclic Materials’ Mesa, Arizona site, the very first scale-up of a commercial plant for recycling and local production of rare earths in the US, with a focus on heavy and light rare earth magnets. The recycling of magnet-containing end-of-life (EOL) scrap and magnet production waste is the fastest way to the production of magnet rare earth elements (REEs) in Western coun
SLB Announces Fourth-Quarter and Full-Year 2025 Results, Increases Dividend and Commits to Return More Than $4 Billion to Shareholders in 202623.1.2026 12:50:00 CET | Press release
Fourth-quarter revenue of $9.75 billion increased 9% sequentially and 5% year on year Fourth-quarter GAAP EPS of $0.55 increased 10% sequentially and decreased 29% year on year Fourth-quarter EPS, excluding charges and credits, of $0.78 increased 13% sequentially and declined 15% year on year Fourth-quarter net income attributable to SLB of $824 million increased 12% sequentially and decreased 25% year on year Fourth-quarter adjusted EBITDA of $2.33 billion increased 13% sequentially and decreased 2% year on year Fourth-quarter cash flow from operations was $3.01 billion and free cash flow was $2.29 billion Board approved a 3.5% increase in quarterly cash dividend to $0.295 per share Full-year revenue of $35.71 billion decreased 2% year on year Full-year GAAP EPS of $2.35 decreased 24% year on year Full-year EPS, excluding charges and credits, of $2.93 decreased 14% year on year Full-year net income attributable to SLB of $3.37 billion decreased 24% year on year Full-year adjusted EBIT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom